Shop by goal
Popular compounds
Research resources
Recently viewed
FDA Panel Votes to Loosen Peptide Restrictions
In a run of razor-thin votes on July 23–24, 2026, an FDA advisory committee sided with compounders — and against the agency’s own scientists. Here is the scoreboard.
By New-U Research Compounds · July 24, 2026 · 9 min read
Recommendation, not approval. The panel’s advice is non-binding, and FDA reviewers opposed all four. Scroll for the full breakdown.
The story in one paragraph: On July 23–24, 2026 , the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157, KPV, TB-500 (all 8–6) and MOTS-c (7–5) to the 503A Bulk Drug Substances List — the step that would let specialised compounding pharmacies prepare them for prescriptions. Every vote was close, and the FDA’s own scientists had recommended against all of them. The committee’s advice is non-binding : this is about compounding eligibility , not drug approval.
For three years peptides like BPC-157 and TB-500 have lived in a regulatory grey zone — widely sold online, hyped by wellness influencers, and yet not approved for human use. On July 23, 2026 that began to shift. An FDA advisory panel narrowly voted to loosen the restrictions, clearing a major hurdle toward making several popular peptides available by prescription through compounding pharmacies. Below is exactly what the committee decided, why it’s controversial, and what still has to happen next.
What the panel actually voted on
The committee did not vote to approve any peptide as a drug. It voted on whether four bulk substances should be added to the 503A Bulk Drug Substances List — the list of ingredients that state-licensed 503A compounding pharmacies are permitted to use when they mix a medication that isn’t available from a standard manufacturer. Getting onto that list is the gateway to legal, prescription-based compounding for human patients.
The four peptides considered on July 23 were reviewed in both their “free base” and “acetate” salt forms. The panel voted in favour of every one:
The vote-by-vote scoreboard (July 23, 2026):
Three more peptides — Emideltide (DSIP), Semax and Epitalon — were slated for the panel’s July 24 session, part of a longer list of roughly twelve peptides under reconsideration.
The twist: the panel overruled FDA’s own scientists
What makes this vote notable isn’t just that it passed — it’s that it passed over the objections of the agency’s own reviewers . Ahead of the meeting, FDA scientists concluded that none of the substances should be added to the 503A list, pointing to gaps in chemical characterisation and, above all, a lack of human safety and efficacy data. Several of these peptides have only been studied in animals.
That tension played out in the room. One dissenting panelist warned that the committee was “responding to a market-induced demand rather than a decision based in solid science.” Panel member Elizabeth Rebello, a pharmacist and anaesthesiologist, said she voted no on BPC-157 “because of the lack of efficacy data” and “safety concerns,” according to Reuters. Members who voted yes were reported to cite “the greater good” and “medical freedom.”
Coverage also noted that several people who work for clinics or businesses that sell peptides sat on the panel — a conflict-of-interest question that shadows how much weight the recommendations should carry.
Why this is happening now
Injectable peptides exploded in the online wellness community after GLP-1 weight-loss drugs went mainstream. On TikTok they’re marketed in “stacks” under banners like “biohacking” and “looksmaxxing,” with unproven claims about healing, skin, and muscle — a trend especially visible among young men and teenage boys.
Politics matters too. Peptide restrictions were tightened under the previous administration when FDA officials found the drugs didn’t meet safety requirements. Health Secretary Robert F. Kennedy Jr. , who has called himself a “big fan” of peptides and disclosed personal use, has publicly pushed to ease those curbs. The July 2026 meeting is the clearest sign yet of that policy shift reaching the advisory process.
What the vote does — and doesn’t — mean
It does: move BPC-157, KPV, TB-500 and MOTS-c one important step toward being eligible for 503A pharmacy compounding, which is how they could eventually reach patients by prescription.
It does not: make any of them an FDA-approved drug; bind the FDA to anything (the recommendation is advisory); or change the status of research-grade material, which remains research-use-only.
Advisory-committee recommendations often carry significant weight, and the FDA frequently follows them — but not always. Any actual change to compounding eligibility still requires the agency to act and, typically, to complete formal rulemaking. In other words, “the panel voted yes” in July 2026 is a long way from “available at your pharmacy.”
The safety caveat that hasn’t gone away
The evidence gap the FDA reviewers flagged is real. BPC-157, one of the most popular peptides online, is derived from a stomach protein and has mostly been studied in animals; the U.S. Anti-Doping Agency notes that because it hasn’t been extensively studied in humans, “no-one knows if there is a safe dose.” It’s a prohibited substance in sport under the World Anti-Doping Agency. A favourable compounding vote doesn’t retroactively create the human trials that don’t yet exist — it just changes the regulatory pathway.
Where research use sits
Independent of the compounding debate, the research-use-only lane is unchanged. Research compounds are supplied to laboratories as reagents, labelled research use only and not for human consumption . The 503A story concerns the pharmacy-compounding pathway for human prescriptions; it does not alter how research-grade material is positioned, labelled, or handled.
Frequently Asked Questions
Did the FDA approve peptides in 2026? No. An advisory panel voted to recommend adding four peptides to the 503A compounding list. That’s about compounding eligibility, not drug approval, and it’s non-binding.
How did the panel vote on each peptide? BPC-157 8–6, KPV 8–6, TB-500 8–6, and MOTS-c 7–5 — all in favour, all close.
Why did FDA scientists oppose them? They cited gaps in characterisation and a lack of human safety and efficacy data; several peptides have only been studied in animals.
Does this make BPC-157 or TB-500 legal to use? Not by itself. It’s a step toward compounding eligibility, not approval, and research-grade material stays research-use-only.
Related Reading
Sources: reporting on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee meeting by BioPharma Dive, BBC News, NPR, The Hill, and the FDA’s July 23–24, 2026 PCAC meeting page. Vote counts reflect contemporaneous reporting. External links are for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified Research Compounds
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
At New-U, we believe better conversations start with better information. For laboratory research use only. Not for human consumption.
Research-grade · >99% HPLC purity · COA per lot
Buy research peptides from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io
[image: Illustration of a narrowly divided FDA advisory committee chamber lit teal and violet, symbolising the split peptide vote]